Emil Grieco, MD
Urology · Naples, FLNPI 1013031384
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 36.1% of the total. Reporting peaked in 2022 at $131 and has fallen 60.1% since, to $52 in 2024. That places this record below the midpoint for urology clinicians in FL, where the typical reported total is $3,881.
Across 22 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$144
- Boston Scientific$64
- Pfizer$26
- Blue Earth Diagnostics$26
- Endo Pharmaceuticals Inc.$25
- Urovant Sciences Inc$21
- plus $93 from 6 others
What the payments were for
- Food & beverage$398100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 9 | $144 |
| Boston Scientific | 2 | $64 |
| Pfizer | 2 | $26 |
| Blue Earth Diagnostics | 1 | $26 |
| Endo Pharmaceuticals Inc. | 1 | $25 |
| Urovant Sciences Inc | 1 | $21 |
| Healthtronics Stone Solutions, LLC | 1 | $19 |
| Axonics, Inc. | 1 | $17 |
| Tolmar, Inc. | 1 | $17 |
| Olympus America Inc. | 1 | $15 |
| Tolmar Pharmaceuticals, Inc. | 1 | $14 |
| Antares Pharma, Inc. | 1 | $11 |
How this compares
$398 in reported general payments places this provider in the 15th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 118 | $2,504 |
| Methenamine Hippurate | 20 | $2,029 |
| Doxazosin Mesylate | 77 | $1,746 |
| Finasteride | 55 | $547 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 27 | $448 |
| Ciprofloxacin Hcl | 14 | $170 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $124 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $80 |
| Allopurinol | 16 | $67 |
Paid to pharmacies, not to this prescriber.
Other urology in Naples
- Rolando RiveraNaples$437K
- David WilkinsonNaples$216K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
- Juan SuarezCoral Gables$276K
- Michael McDonaldCelebration$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.